<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DUTASTERIDE</span><br/>(du-tas'ter-ide)<br/><span class="topboxtradename">Avodart<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">antiandrogen</span>; <span class="classification">5-alpha reductase inhibitor</span><br/><b>Prototype: </b>Finasteride<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Specific inhibitor of the steroid 5-alpha-reductase, an enzyme necessary to convert testosterone into the potent androgen
         5-alpha-dihydrotestosterone (DHT) in the prostate gland.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases the production of testosterone in the prostate gland.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of benign prostatic hypertrophy (BPH).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of male pattern baldness.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to dutasteride or finasteride; pregnancy (category X), lactation, and children.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment, obstructive uropathy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">BPH</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.5 mg once daily<br/><br/><span class="indicationtitle">Male Pattern Baldness</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.250.5 mg once daily<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not handle capsules if you are or may become pregnant because of the potential for absorption of dutasteride and the subsequent
            risk to a developing male fetus.
         </li>
<li>Do not open or crush capsules. They must be swallowed whole.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Endocrine:</span> Gynecomastia. <span class="typehead">Urogenital:</span> Ejaculation dysfunction, impotence, decreased libido. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Diltiazem,</b> <b>verapamil</b> may decrease clearance of dutasteride. <span class="typehead">Herbal:</span> May see exaggerated effects with <b>Saw Palmetto.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. 60% bioavailability. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4 to one active and 2 inactive metabolites. <span class="typehead">Elimination:</span> Primarily excreted in feces. <span class="typehead">Half-Life:</span> 5 weeks. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor voiding patterns, assessing for ease of starting a stream, frequency, and urgency.</li>
<li>Lab tests: Monitor baseline PSA and again at 36 mo to establish new baseline to use to assess potentially cancer-related
            changes in PSA. After 6 mo of treatment, obtained PSA values should be doubled for comparison with normal values in untreated
            men.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not donate blood until at least 6 mo following last dose to prevent administration of dutasteride to a pregnant female
            transfusion recipient.
         </li>
<li>Ejaculate volume might be decreased during treatment but this does not seem to interfere with normal sexual function.</li>
<li>Note that the incidence of most drug-related sexual adverse events (impotence, decreased libido, and ejaculation disorder)
            typically decrease with duration of treatment.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>